Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway
Juncheng Guo(Hainan General Hospital), Jinfang Zheng(Hainan General Hospital)
Cited by 11
Related Papers
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2025|39